1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Paion AG

Paion AG

PAIOF
Paion AGUS flagOther OTC
0.07
USD
- -
- -
526,847.00Market Cap
Paion AG
PAIOF
(Other OTC)

Recent

price

0.07

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
2.35
1.23
0.51
1.47
1.04
8.59
1.35
0.84
0.01
0.79
0.97
0.43
1.21
2.99
1.02
4.66
3
Revenue per Share
-5.1
-4.91
-4.31
-3.05
-4.4
5.13
-0.71
-2.22
-5.43
-3.71
-2.01
-1.56
-1.06
0.34
-3.11
-0.08
0.34
Basic EPS, GAAP
-6.53
-1.93
-4.17
-2.7
-2.38
4.95
-0.56
-2.95
-5.06
-2.17
-2.95
-2.02
-0.43
0.14
-5.77
0.61
0.14
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
13.23
-21.37
-22.42
-25.26
-28.93
-23.71
-24.29
-14.67
-16.97
-19.05
-18.28
-18.41
-18.69
-18.2
-19.48
-19.19
-18.23
Book Value per Share
17.08
7.87
2.62
0.46
-1.44
3.76
3.13
14.45
6.19
4.11
3.79
2.92
1.9
2.96
-1.81
-1.82
2.97
Tangible Book Value per Share
2
3
3
3
3
3
3
4
5
5
6
6
7
7
7
7
7
Basic Weighted Avg Shares
5
3
2
4
3
27
4
3
- -
4
6
3
8
20
7
33
20
Sales/Revenue/Turnover
-260.47
-435.81
-847.58
-201.88
-412.18
70.31
-86.8
-348.67
-48,946.78
-569.6
-273.09
-463.11
-126.53
9.38
-309.75
4.53
-22.36
Operating Margin (%)
1
1
- -
1
7
- -
- -
- -
- -
1
- -
- -
- -
- -
2
2
- -
Depreciation Expense
-11
-13
-13
-9
-14
16
-2
-9
-28
-20
-12
-10
-7
2
-22
-1
2
Net Income, GAAP
- -
- -
- -
- -
- -
12.4
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-216.9
-397.32
-850.3
-206.82
-421.16
59.71
-52.32
-263.46
-39,394.65
-472.05
-208.11
-359.36
-87.7
11.31
-305.64
-1.74
11.31
Profit Margin (%)
41
33
20
12
5
13
10
59
32
22
23
19
12
19
5
5
19
Working Capital
- -
- -
- -
- -
7
- -
- -
- -
- -
- -
- -
- -
- -
- -
19
19
- -
LT Debt
36
32
19
12
- -
16
13
63
36
25
25
21
15
21
7
7
21
Total Equity
- -
- -
- -
- -
- -
112.56
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-21.38
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'20
Sep'20
Dec'20
ST Debt
1
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
171
165
155

Working Capital

FRC

•

in mil. unless spec.
Jun'20
Sep'20
Dec'20
Total Current Assets
19
- -
26
Cash, Cash Equivalents & STI
12
25
20
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
1
Total Current Liabilities
9
8
7
Payables & Accruals
- -
- -
- -
ST Debt
1
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.86%
-14.97%
-5.49%
Free Cash Flow
-438.1%
-994.49%
-110.78%
Net Income, GAAP
-101.76%
-271.33%
-97.34%
Sales/Revenue/Turnover
627.22%
117.05%
366.44%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
7
2022
4
- -
- -
- -
33
2023
5
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.9
- -
- -
- -
-3.11
2022
-0.53
- -
- -
- -
-0.08
2023
-0.63
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF)
Little Green Pharma Ltd (LGP.AX)
TransCanna Holdings Inc. (TCNAF)
Dezhan Healthcare Company Limited (000813.SZ)
Caplin Point Laboratories Limited (CAPLIPOINT.NS)
Bafna Pharmaceuticals Limited (BAFNAPHARM.BO)
Business
Paion AG (PAIOF), a specialty pharmaceutical company, develops and commercializes innovative drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide; its lead product is remimazolam (Byfavo), an ultra-short-acting intravenous benzodiazepine sedative/anesthetic approved for procedural sedation in the U.S., EU/EEA/UK, China, and South Korea, and for general anesthesia in the EU/EEA, Japan, the Philippines, and South Korea; it also markets Angiotensin II (GIAPREZA), a vasoconstrictor for refractory hypotension in adults with septic or distributive shock, and eravacycline (XERAVA), a fluorocycline antibiotic for complicated intra-abdominal infections in adults, primarily in selected European countries. The company maintains partnerships and license agreements with entities including Cosmo Pharmaceuticals, Hana Pharm, Yichang Humanwell, Mundipharma, and Viatris for distribution in various territories. Founded in 2000 and headquartered in Aachen, Germany, Paion AG focuses on anesthesia and critical care segments, targeting hospitals and healthcare providers across Europe, the U.S., Asia, and other regions. In a major recent development, following insolvency proceedings initiated in late 2023 due to financing irregularities, Paion AG sold its business operations to Humanwell Healthcare Group in March 2024, with operations continuing as an independent subsidiary under the name PAION Pharma GmbH since February 2024, preserving jobs and expertise in anesthesia and critical care while enhancing global distribution and R&D capabilities through the strategic partnership.